A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2018
At a glance
- Drugs NBS 03 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 According to a Caladrius Biosciences media release, this study was published in Clinical Immunology.
- 19 Jul 2017 According to a Caladrius Biosciences media release, two year results from this study were published in journal Translational Medicine.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History